The genomic landscape of myeloid neoplasms with myelodysplasia and its clinical implications

Luca Malcovati, Ilaria Ambaglio, Chiara Elena

Research output: Contribution to journalArticle

Abstract

Purpose of review: This article will review the most recent advances in the understanding of the genetic basis of myeloid neoplasms with myelodysplasia and will discuss its clinical implications. Recent findings: Recurrent somatic mutations have been identified in about 90% of patients with myeloid neoplasms with myelodysplasia, involving genes of RNA splicing, DNA methylation, histone modification, transcription regulation, DNA repair, signal transduction, and cohesin complex. Somatic mutations are acquired in a linear manner in a multipotent hematopoietic stem cell, resulting in a growth advantage at the stem cell level and in defective differentiation and maturation of hematopoietic precursors. Recently, evidence has been provided of age-related hematopoietic clones, driven by mutations of genes recurrently mutated in myeloid neoplasms. These hematopoietic clones may represent either premalignant clones with the potential to progress to myeloid neoplasm or small malignant clones at a preclinical stage. Summary: The available evidence clearly indicates that greater understanding of the molecular basis of myeloid neoplasms with myelodysplasia has relevant implications in the classification of these disorders, as well as in predicting disease risk and response to specific treatment modalities, and may open avenues of research leading to novel therapeutic options and personalized treatment in the individual patient.

Original languageEnglish
Pages (from-to)551-559
Number of pages9
JournalCurrent Opinion in Oncology
Volume27
Issue number6
DOIs
Publication statusPublished - Oct 9 2015

Fingerprint

Clone Cells
Neoplasms
Mutation
Histone Code
Multipotent Stem Cells
RNA Splicing
DNA Methylation
Hematopoietic Stem Cells
DNA Repair
Genes
Signal Transduction
Stem Cells
Therapeutics
Growth
Research

Keywords

  • Clonal hematopoiesis
  • Myelodysplasia
  • Myeloid neoplasm
  • RNA splicing
  • Somatic mutation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The genomic landscape of myeloid neoplasms with myelodysplasia and its clinical implications. / Malcovati, Luca; Ambaglio, Ilaria; Elena, Chiara.

In: Current Opinion in Oncology, Vol. 27, No. 6, 09.10.2015, p. 551-559.

Research output: Contribution to journalArticle

@article{afc55838baa141748dab84f5085b35e5,
title = "The genomic landscape of myeloid neoplasms with myelodysplasia and its clinical implications",
abstract = "Purpose of review: This article will review the most recent advances in the understanding of the genetic basis of myeloid neoplasms with myelodysplasia and will discuss its clinical implications. Recent findings: Recurrent somatic mutations have been identified in about 90{\%} of patients with myeloid neoplasms with myelodysplasia, involving genes of RNA splicing, DNA methylation, histone modification, transcription regulation, DNA repair, signal transduction, and cohesin complex. Somatic mutations are acquired in a linear manner in a multipotent hematopoietic stem cell, resulting in a growth advantage at the stem cell level and in defective differentiation and maturation of hematopoietic precursors. Recently, evidence has been provided of age-related hematopoietic clones, driven by mutations of genes recurrently mutated in myeloid neoplasms. These hematopoietic clones may represent either premalignant clones with the potential to progress to myeloid neoplasm or small malignant clones at a preclinical stage. Summary: The available evidence clearly indicates that greater understanding of the molecular basis of myeloid neoplasms with myelodysplasia has relevant implications in the classification of these disorders, as well as in predicting disease risk and response to specific treatment modalities, and may open avenues of research leading to novel therapeutic options and personalized treatment in the individual patient.",
keywords = "Clonal hematopoiesis, Myelodysplasia, Myeloid neoplasm, RNA splicing, Somatic mutation",
author = "Luca Malcovati and Ilaria Ambaglio and Chiara Elena",
year = "2015",
month = "10",
day = "9",
doi = "10.1097/CCO.0000000000000229",
language = "English",
volume = "27",
pages = "551--559",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - The genomic landscape of myeloid neoplasms with myelodysplasia and its clinical implications

AU - Malcovati, Luca

AU - Ambaglio, Ilaria

AU - Elena, Chiara

PY - 2015/10/9

Y1 - 2015/10/9

N2 - Purpose of review: This article will review the most recent advances in the understanding of the genetic basis of myeloid neoplasms with myelodysplasia and will discuss its clinical implications. Recent findings: Recurrent somatic mutations have been identified in about 90% of patients with myeloid neoplasms with myelodysplasia, involving genes of RNA splicing, DNA methylation, histone modification, transcription regulation, DNA repair, signal transduction, and cohesin complex. Somatic mutations are acquired in a linear manner in a multipotent hematopoietic stem cell, resulting in a growth advantage at the stem cell level and in defective differentiation and maturation of hematopoietic precursors. Recently, evidence has been provided of age-related hematopoietic clones, driven by mutations of genes recurrently mutated in myeloid neoplasms. These hematopoietic clones may represent either premalignant clones with the potential to progress to myeloid neoplasm or small malignant clones at a preclinical stage. Summary: The available evidence clearly indicates that greater understanding of the molecular basis of myeloid neoplasms with myelodysplasia has relevant implications in the classification of these disorders, as well as in predicting disease risk and response to specific treatment modalities, and may open avenues of research leading to novel therapeutic options and personalized treatment in the individual patient.

AB - Purpose of review: This article will review the most recent advances in the understanding of the genetic basis of myeloid neoplasms with myelodysplasia and will discuss its clinical implications. Recent findings: Recurrent somatic mutations have been identified in about 90% of patients with myeloid neoplasms with myelodysplasia, involving genes of RNA splicing, DNA methylation, histone modification, transcription regulation, DNA repair, signal transduction, and cohesin complex. Somatic mutations are acquired in a linear manner in a multipotent hematopoietic stem cell, resulting in a growth advantage at the stem cell level and in defective differentiation and maturation of hematopoietic precursors. Recently, evidence has been provided of age-related hematopoietic clones, driven by mutations of genes recurrently mutated in myeloid neoplasms. These hematopoietic clones may represent either premalignant clones with the potential to progress to myeloid neoplasm or small malignant clones at a preclinical stage. Summary: The available evidence clearly indicates that greater understanding of the molecular basis of myeloid neoplasms with myelodysplasia has relevant implications in the classification of these disorders, as well as in predicting disease risk and response to specific treatment modalities, and may open avenues of research leading to novel therapeutic options and personalized treatment in the individual patient.

KW - Clonal hematopoiesis

KW - Myelodysplasia

KW - Myeloid neoplasm

KW - RNA splicing

KW - Somatic mutation

UR - http://www.scopus.com/inward/record.url?scp=84944066161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944066161&partnerID=8YFLogxK

U2 - 10.1097/CCO.0000000000000229

DO - 10.1097/CCO.0000000000000229

M3 - Article

C2 - 26352542

AN - SCOPUS:84944066161

VL - 27

SP - 551

EP - 559

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 6

ER -